Century Therapeutics, Inc. (IPSC) Insider Trading

Last 12 months

Insiders bought $97k and sold $86k on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan.

Net open-market

+$11k

3 buys · 20 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

2 / 4

executives and directors

Last open-market buy

Dec 2025

Dec 22, 2025

Get an email when IPSC's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 14	Gregory Russotti See Remarks	SoldNo plan	2,587	$1.93	$5k	0.4%	Form 4
Sep 14	Douglas Carr SVP Finance & Operations	SoldNo plan	1,658	$1.93	$3k	0.3%	Form 4
Sep 8	Gregory Russotti See Remarks	SoldNo plan	534	$2.05	$1k	<0.1%	Form 4
Sep 8	Douglas Carr SVP Finance & Operations	SoldNo plan	254	$2.05	$521	<0.1%	Form 4
Aug 3	Douglas Carr SVP Finance & Operations	SoldNo plan	275	$1.98	$545	<0.1%	Form 4
Jun 12	Gregory Russotti See Remarks	SoldNo plan	2,584	$2.23	$6k	0.4%	Form 4
Jun 12	Douglas Carr SVP Finance & Operations	SoldNo plan	1,654	$2.23	$4k	0.3%	Form 4
Jun 8	Gregory Russotti See Remarks	SoldNo plan	524	$2.11	$1k	<0.1%	Form 4
Jun 8	Douglas Carr SVP Finance & Operations	SoldNo plan	249	$2.11	$525	<0.1%	Form 4
May 4	Douglas Carr SVP Finance & Operations	SoldNo plan	264	$2.34	$618	<0.1%	Form 4
Mar 12	Gregory Russotti See Remarks	SoldNo plan	10,076	$2.55	$26k	1.6%	Form 4
Mar 12	Douglas Carr SVP Finance & Operations	SoldNo plan	7,043	$2.55	$18k	1.4%	Form 4
Mar 9	Gregory Russotti See Remarks	SoldNo plan	479	$2.54	$1k	<0.1%	Form 4
Mar 9	Douglas Carr SVP Finance & Operations	SoldNo plan	247	$2.54	$627	<0.1%	Form 4
Feb 3	Douglas Carr SVP Finance & Operations	SoldNo plan	323	$1.82	$588	<0.1%	Form 4
Dec 22, 2025	Chad Cowan Chief Scientific Officer	Bought	58,060	$0.85	$49k	5.8%	Form 4
Dec 12, 2025	Brent Pfeiffenberger President and CEO	Bought	52,000	$0.58	$30k	1.6%	Form 4
Dec 8, 2025	Gregory Russotti See Remarks	SoldNo plan	526	$0.53	$279	0.1%	Form 4
Dec 8, 2025	Douglas Carr SVP Finance & Operations	SoldNo plan	257	$0.53	$136	<0.1%	Form 4
Nov 20, 2025	Chad Cowan Chief Scientific Officer	SoldNo plan	5,462	$0.50	$3k	0.5%	Form 4
Nov 19, 2025	Brent Pfeiffenberger President and CEO	Bought	35,000	$0.50	$18k	1.1%	Form 4
Nov 17, 2025	Brent Pfeiffenberger President and CEO	SoldNo plan	32,456	$0.45	$15k	1.0%	Form 4
Nov 3, 2025	Douglas Carr SVP Finance & Operations	SoldNo plan	292	$0.59	$172	<0.1%	Form 4
Sep 8, 2025	Douglas Carr SVP Finance & Operations	SoldNo plan	263	$0.50	$132	<0.1%	Form 4
Sep 8, 2025	Brent Pfeiffenberger President and CEO	SoldNo plan	488	$0.50	$244	<0.1%	Form 4
Sep 8, 2025	Gregory Russotti See Remarks	SoldNo plan	539	$0.50	$270	0.1%	Form 4
Aug 4, 2025	Douglas Carr SVP Finance & Operations	SoldNo plan	296	$0.53	$157	<0.1%	Form 4
Jun 9, 2025	Douglas Carr SVP Finance & Operations	SoldNo plan	4,904	$0.62	$3k	1.2%	Form 4
Jun 9, 2025	Adrienne Farid Chief Operations Officer	SoldNo plan	552	$0.62	$342	0.2%	Form 4
Jun 9, 2025	Brent Pfeiffenberger President and CEO	SoldNo plan	475	$0.62	$295	<0.1%	Form 4
Jun 9, 2025	Gregory Russotti See Remarks	SoldNo plan	526	$0.62	$326	0.1%	Form 4
May 16, 2025	Brent Pfeiffenberger President and CEO	SoldNo plan	29,552	$0.55	$16k	1.7%	Form 4
May 5, 2025	Adrienne Farid Chief Operations Officer	SoldNo plan	1,024	$0.55	$563	0.4%	Form 4
May 5, 2025	Douglas Carr SVP Finance & Operations	SoldNo plan	295	$0.55	$162	<0.1%	Form 4
Mar 10, 2025	Brent Pfeiffenberger President and CEO	SoldNo plan	2,235	$0.62	$1k	0.1%	Form 4
Mar 10, 2025	Gregory Russotti See Remarks	SoldNo plan	2,360	$0.62	$1k	0.5%	Form 4
Mar 10, 2025	Adrienne Farid Chief Operations Officer	SoldNo plan	2,359	$0.62	$1k	0.9%	Form 4
Mar 10, 2025	Douglas Carr SVP Finance & Operations	SoldNo plan	1,240	$0.62	$769	0.3%	Form 4
Feb 18, 2025	Brent Pfeiffenberger President and CEO	SoldNo plan	34,712	$0.78	$27k	2.8%	Form 4
Feb 3, 2025	Adrienne Farid Chief Operations Officer	SoldNo plan	1,054	$0.78	$822	0.8%	Form 4

Sep 14No plan
Gregory Russotti
See Remarks · sold 2,587 at $1.93
$5k
0.4% of stake
Sep 14No plan
Douglas Carr
SVP Finance & Operations · sold 1,658 at $1.93
$3k
0.3% of stake
Sep 8No plan
Gregory Russotti
See Remarks · sold 534 at $2.05
$1k
<0.1% of stake
Sep 8No plan
Douglas Carr
SVP Finance & Operations · sold 254 at $2.05
$521
<0.1% of stake
Aug 3No plan
Douglas Carr
SVP Finance & Operations · sold 275 at $1.98
$545
<0.1% of stake
Jun 12No plan
Gregory Russotti
See Remarks · sold 2,584 at $2.23
$6k
0.4% of stake
Jun 12No plan
Douglas Carr
SVP Finance & Operations · sold 1,654 at $2.23
$4k
0.3% of stake
Jun 8No plan
Gregory Russotti
See Remarks · sold 524 at $2.11
$1k
<0.1% of stake
Jun 8No plan
Douglas Carr
SVP Finance & Operations · sold 249 at $2.11
$525
<0.1% of stake
May 4No plan
Douglas Carr
SVP Finance & Operations · sold 264 at $2.34
$618
<0.1% of stake
Mar 12No plan
Gregory Russotti
See Remarks · sold 10,076 at $2.55
$26k
1.6% of stake
Mar 12No plan
Douglas Carr
SVP Finance & Operations · sold 7,043 at $2.55
$18k
1.4% of stake
Mar 9No plan
Gregory Russotti
See Remarks · sold 479 at $2.54
$1k
<0.1% of stake
Mar 9No plan
Douglas Carr
SVP Finance & Operations · sold 247 at $2.54
$627
<0.1% of stake
Feb 3No plan
Douglas Carr
SVP Finance & Operations · sold 323 at $1.82
$588
<0.1% of stake
Dec 22, 2025
Chad Cowan
Chief Scientific Officer · bought 58,060 at $0.85
$49k
5.8% of stake
Dec 12, 2025
Brent Pfeiffenberger
President and CEO · bought 52,000 at $0.58
$30k
1.6% of stake
Dec 8, 2025No plan
Gregory Russotti
See Remarks · sold 526 at $0.53
$279
0.1% of stake
Dec 8, 2025No plan
Douglas Carr
SVP Finance & Operations · sold 257 at $0.53
$136
<0.1% of stake
Nov 20, 2025No plan
Chad Cowan
Chief Scientific Officer · sold 5,462 at $0.50
$3k
0.5% of stake
Nov 19, 2025
Brent Pfeiffenberger
President and CEO · bought 35,000 at $0.50
$18k
1.1% of stake
Nov 17, 2025No plan
Brent Pfeiffenberger
President and CEO · sold 32,456 at $0.45
$15k
1.0% of stake
Nov 3, 2025No plan
Douglas Carr
SVP Finance & Operations · sold 292 at $0.59
$172
<0.1% of stake
Sep 8, 2025No plan
Douglas Carr
SVP Finance & Operations · sold 263 at $0.50
$132
<0.1% of stake
Sep 8, 2025No plan
Brent Pfeiffenberger
President and CEO · sold 488 at $0.50
$244
<0.1% of stake
Sep 8, 2025No plan
Gregory Russotti
See Remarks · sold 539 at $0.50
$270
0.1% of stake
Aug 4, 2025No plan
Douglas Carr
SVP Finance & Operations · sold 296 at $0.53
$157
<0.1% of stake
Jun 9, 2025No plan
Douglas Carr
SVP Finance & Operations · sold 4,904 at $0.62
$3k
1.2% of stake
Jun 9, 2025No plan
Adrienne Farid
Chief Operations Officer · sold 552 at $0.62
$342
0.2% of stake
Jun 9, 2025No plan
Brent Pfeiffenberger
President and CEO · sold 475 at $0.62
$295
<0.1% of stake
Jun 9, 2025No plan
Gregory Russotti
See Remarks · sold 526 at $0.62
$326
0.1% of stake
May 16, 2025No plan
Brent Pfeiffenberger
President and CEO · sold 29,552 at $0.55
$16k
1.7% of stake
May 5, 2025No plan
Adrienne Farid
Chief Operations Officer · sold 1,024 at $0.55
$563
0.4% of stake
May 5, 2025No plan
Douglas Carr
SVP Finance & Operations · sold 295 at $0.55
$162
<0.1% of stake
Mar 10, 2025No plan
Brent Pfeiffenberger
President and CEO · sold 2,235 at $0.62
$1k
0.1% of stake
Mar 10, 2025No plan
Gregory Russotti
See Remarks · sold 2,360 at $0.62
$1k
0.5% of stake
Mar 10, 2025No plan
Adrienne Farid
Chief Operations Officer · sold 2,359 at $0.62
$1k
0.9% of stake
Mar 10, 2025No plan
Douglas Carr
SVP Finance & Operations · sold 1,240 at $0.62
$769
0.3% of stake
Feb 18, 2025No plan
Brent Pfeiffenberger
President and CEO · sold 34,712 at $0.78
$27k
2.8% of stake
Feb 3, 2025No plan
Adrienne Farid
Chief Operations Officer · sold 1,054 at $0.78
$822
0.8% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch IPSC, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Biological Products, (No Diagnostic Substances)

KYMRKymera Therapeutics Inc.

AUTLAutolus Therapeutics plc

AGENAgenus Inc.

FDMT4D Molecular Therapeutics, Inc.

RGNXRegenxbio Inc.

PLXProtalix Biotherapeutics Inc.

MGTXMeiraGTx Holdings plc

CGENCompugen Ltd.

Spot a number that looks wrong? Check it in IPSC's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IPSC

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.